Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

BACKGROUND: This study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of the first-in-class dual mammalian target of rapamycin complex (mTORC)1/mTORC2 inhibitor, AZD8055. METHODS: Patients with advanced solid malignancies or lymphomas were recruited into this phase I, open-...

Descripción completa

Detalles Bibliográficos
Autores principales: Naing, A, Aghajanian, C, Raymond, E, Olmos, D, Schwartz, G, Oelmann, E, Grinsted, L, Burke, W, Taylor, R, Kaye, S, Kurzrock, R, Banerji, U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461162/
https://www.ncbi.nlm.nih.gov/pubmed/22935583
http://dx.doi.org/10.1038/bjc.2012.368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461162/
https://www.ncbi.nlm.nih.gov/pubmed/22935583
http://dx.doi.org/10.1038/bjc.2012.368

Ejemplares similares